Insmed (INSM) EBT Margin (2010 - 2026)
Insmed (INSM) posted EBT Margin of 2.67% for Q2 2026, up 94.95% on a QoQ basis from 52.98% in Q1 2026, and up 29565.0% year-over-year from N/an in Q2 2025.
Powered by 
Analysis
Insmed (INSM) EBT Margin (2010 - 2026) Analysis & Trends
Insmed has reported EBT Margin for 12 years, with the latest figure at 2.67% in Q2 2026.
- On a quarterly basis, EBT Margin rose 29565.0% year-over-year to 2.67% in Q2 2026; TTM through Jun 2026 was 76.4%, a 18231.0% increase from a year earlier, with the FY2025 full-year figure at 209.71%, up 4051.0% from the prior year.
- EBT Margin was 2.67% for Q2 2026 at Insmed, up from 52.98% in the prior quarter.
- The five-year high for EBT Margin was 2.67% in Q2 2026, with the low at 331.83% in Q2 2024.
- Average EBT Margin over 5 years is 209.94%, with a median of 222.72% recorded in 2023.
- The sharpest annual moves came in 2023 and 2026: EBT Margin plunged 17043 bps in 2023, then soared 29565 bps in 2026.
- Over 5 years, EBT Margin stood at 269.81% in 2022, then increased by 18 bps to 221.12% in 2023, then retreated by 1 bps to 224.32% in 2024, then surged by 45 bps to 123.91% in 2025, then jumped by 98 bps to 2.67% in 2026.
- The last three EBT Margin figures came in at 2.67% (Q2 2026), 52.98% (Q1 2026), and 123.91% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 4.84% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -2.67% |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | -813.16% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.67% |
| Mar 31, 2026 | -52.98% |
| Dec 31, 2025 | -123.91% |
| Sep 30, 2025 | -259.02% |
| Jun 30, 2025 | -298.32% |
| Mar 31, 2025 | -275.44% |
| Dec 31, 2024 | -224.32% |
| Sep 30, 2024 | -234.96% |
| Jun 30, 2024 | -331.83% |
| Mar 31, 2024 | -207.29% |
| Dec 31, 2023 | -221.12% |
| Sep 30, 2023 | -200.31% |
| Jun 30, 2023 | -316.30% |
| Mar 31, 2023 | -244.24% |
| Dec 31, 2022 | -269.81% |
| Sep 30, 2022 | -193.08% |
| Jun 30, 2022 | -145.88% |
| Mar 31, 2022 | -177.45% |
| Dec 31, 2021 | -201.37% |
| Sep 30, 2021 | -246.58% |